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Summary The aim of this study was to elucidate endothelial dysfunction due to chronic
cigarette smoking in young smokers and to determine practical markers of the functional
derangement. The subjects were young, healthy, male non-smokers (n = 11) and smokers (n = 9).
Endothelium-dependent and -independent vasodilation was assessed by ﬂow-mediated vasodi-
lation (FMD) and nitroglycerine-induced vasodilation (NID), respectively, and possible markers
of endothelial function were measured. FMD in smokers was signiﬁcantly lower than in con-
trol subjects (5.0± 2.6% and 9.5± 5.2%, p < 0.05). Plasminogen activator inhibitor type 1
(PAI-1) and tissue plasminogen activator levels were signiﬁcantly (p < 0.05) higher in smok-
ers (6.7± 4.5 ng/ml and 4.3± 2.0 ng/ml) compared with control subjects (2.9± 1.9 ng/ml and
3.0± 0.6 ng/ml). Furthermore, PAI-1 levels correlated inversely with FMD (r =−0.451, p < 0.05).
No signiﬁcant differences were observed for NID, or plasma NO2−, NOX, thrombomodulin, von
Willebrand factor, and tissue factor pathway inhibitor levels. Chronic cigarette smoking-induced
the
Carendothelial dysfunction and
in young smokers.
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ntroduction
he vascular endothelium plays a fundamental role in
he regulation of vascular tone, thrombotic balance,
nd inﬂammatory responses [1], and its dysfunction is
onsidered to be one of the causes of pathological con-
itions, such as atherosclerosis, as is shown at an early
tage in the development of atherosclerosis [2,3]. More-
ver, recent studies demonstrated that the severity of
Published by Elsevier Ireland Ltd. All rights reserved.
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Table 1 Baseline characteristics of study subjects.
Controls (n = 11) Smokers (n = 9) p-Values
Age (years) 27± 3 30± 4 ns
BP (mmHg) 120± 10/74± 7 122± 12/76± 4 ns
HR (bpm) 58± 3 65± 8 <0.01
TC (mg/dl) 163± 23 175± 19 ns
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STG (mg/dl) 67± 35
HDLC (mg/dl) 64± 13
BP: blood pressure (systolic/diastolic); HR: heart rate; TC: total ch
ndothelial dysfunction relates to cardiovascular events
4]. Among the risk factors for atherosclerosis, cigarette
moking is a major factor that also exhibits a close
ssociation with coronary artery disease [5]. Indeed,
mpairment of endothelial function, such as reduced
eactive hyperemia and attenuated vasodilatory response
o acetylcholine, has been shown by cigarette smoking
hypercholesterolemia, hypertension, and diabetes mellitus
6—11]. Although the precise mechanisms by which smoking
ould affect endothelial function are not clear, cigarette
moking is known to impair endothelial prostacyclin pro-
uction, increase monocyte—endothelial cell adhesion and
ndothelial adhesion molecule expression, and increase
ndothelial production of angiotensin II [12,13]. The oxi-
ants and free radicals [14—16], as well as nicotine [17] in
he smoke, likely contribute to the endothelial dysfunction.
oreover, impaired ﬁbrinolysis in plasma with chronic
moking may affect endothelial function [18]. In principle,
hanges in intrinsic substances above pathophysiological
hanges could be detected as indices of endothelial impair-
ent by cigarette smoking. Several studies have identiﬁed
he speciﬁc and measurable markers of endothelial dysfunc-
ion, including soluble adhesion molecules, von Willebrand
actor (vWF) and thrombomodulin (TM) [19]. However, such
linical and practical markers have not yet been established
n smokers. Therefore, the purpose of this study was to
xamine the effect of cigarette smoking on endothelial
unction in healthy young adults and search for practical
arkers for endothelial dysfunction in young smokers.
ethods
ubjects
he subjects of this study were young, healthy, male non-
mokers (control subjects: n = 11, mean age 27± 3 years) and
mokers (n = 9, mean age 30± 4 years) (Table 1). Smokers
ere deﬁned as any who had smoked at least 20 cigarettes
er day for the past 5 years. A complete physical examina-
ion was performed prior to the study. The participants were
ree from other risk factors for coronary artery disease and
one was treated with any medications during the study. All
articipants provided informed consent.tudy design
igarette smokers refrained from smoking for at least
h before arrival in the vascular laboratory. The par-
V
t
e
b85± 38 ns
55± 9 ns
erol; TG: triglyceride; HDLC: high-density lipoprotein cholesterol.
icipants rested on beds in supine position for at least
0min before the study. Endothelium-dependent vasodi-
ation and endothelium-independent vasodilation were
easured according to methods that have been described
reviously [20,21]. SONOS-2000 (Hewlett Packard, Andover,
A, USA) equipped with a 7.5MHz ultrasound probe was
sed to measure the internal diameter and ﬂow velocity
f the right brachial artery at a position several centime-
ers below the elbow, where the artery could easily be
etected. Next, a Manechette tourniquet was used to apply
00mmHg of pressure for 5min, and the internal diameter
f the brachial artery was measured at the same location
5—60 s after release of the tourniquet in order to compare
he rate of dilation of the artery before and after reactive
yperemia (endothelium-dependent vasodilation). Arterial
iameter measurements were made at end-diastole (peak
f R wave on electrocardiogram) using electronic calipers.
rterial ﬂow velocity was also measured at baseline and
uring reactive hyperemia using a pulsed Doppler signal
t 70◦ in the center of the artery. Blood ﬂow was calcu-
ated based on the ﬂow velocity and the cross-sectional
rea of the vessel. After a 15-min recovery period, the
nternal diameter of the brachial artery was measured
gain at the same location. Next, 0.3mg of nitroglycer-
ne (NTG) was sprayed into the mouth, and the internal
iameter of the brachial artery was measured at the same
ocation 5min later, to compare the degree of dilation
f the artery before and after endothelium-independent
asodilation.
Before endothelium-dependent vasodilation was mea-
ured, blood samples were taken to measure the plasma
evels of NO2−, NOX (nitrate + nitrite), plasminogen activa-
or inhibitor type 1 (PAI-1), tissue plasminogen activator
t-PA), TM, tissue factor pathway inhibitor (TFPI), and vWF
s indices of endothelial function. NO2− and NOX concentra-
ions were evaluated by the HPLC-Griess system (ENO-10;
ICOM, Kyoto, Japan) as described previously [22,23]. NO2−
nd NOX contamination in the laboratory ware or during
easurement procedure was actively excluded [23,24]. PAI-
, t-PA, TM, and TFPI were measured using enzyme-linked
mmunosorbent assay. vWF was measured by the ristocetin
ofactor assay.
tatistical analysisalues are expressed as the mean± S.D. Unpaired Students’
-test was used to compare between the two groups. Lin-
ar regression analysis was used to examine the association
etween change of FMD and each marker of endothelial
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tFigure 1 Changes in arterial diameter in ﬂow-mediated (FMD)
arterial diameters (%) as a result of FMD and NTG-induced vasod
(n = 11); smokers, subjects who currently smoke (n = 9). *Signiﬁc
function. p-Values < 0.05 were considered to indicate sta-
tistical signiﬁcance.
Results
There were no differences in age, systolic and dias-
tolic blood pressure, total cholesterol, triglyceride, or
high-density lipoprotein cholesterol between smokers and
control subjects (Table 1). Heart rate (HR) was sig-
niﬁcantly higher in smokers compared with control
subjects. The baseline diameter of the brachial artery
was not different between smokers and control subjects
(4.11± 0.31mm and 3.92± 0.24mm, respectively). FMD
in the smokers was signiﬁcantly smaller than those in
the control subjects (5.0± 2.6% and 9.5± 5.2%, respec-
tively, p < 0.05) (Fig. 1). Baseline blood ﬂow velocity
and the increase in the blood ﬂow during reactive
hyperemia were not different between the two groups
r
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Figure 2 Plasma levels of plasminogen activator inhibitor type 1
control subjects. Plasma levels of PAI-1 and t-PA in the control stat
(n = 11); smokers, subjects who currently smoke (n = 9). *Signiﬁcantlnitroglycerine (NTG)-induced vasodilation. Changes in brachial
on are expressed as the mean± S.D. Controls, control subjects
y (p < 0.05) different from the control group.
smokers: 181± 87ml/min, 639± 245% and control sub-
ects: 171± 97ml/min, 718± 363%, respectively). Prior
o NTG administration, the brachial artery diameter
f the two groups was not different (4.10± 0.31mm
nd 3.94± 0.20mm, respectively). NTG-induced vasodila-
ion (NID) was not signiﬁcantly different between the
wo groups (smokers: 15.5± 4.4% and control subjects:
4.8± 3.8%, respectively) (Fig. 1). Signiﬁcantly higher lev-
ls (p < 0.05) of plasma PAI-1 and t-PA were observed in
he smokers (6.7± 4.5 ng/ml and 4.3± 2.0 ng/ml, respec-
ively) compared with the control subjects (2.9± 1.9 ng/ml
nd 3.0± 0.6 ng/ml, respectively) (Fig. 2). Plasma NO2−
0.169± 0.047mol/l and 0.152± 0.095mol/l, respec-
ively) and NOX (26.1± 8.6mol/l and 32.3± 9.6mol/l,
espectively) levels were not different between smokers
nd control subjects (Fig. 3). TM (smokers: 1.9± 0.3 FU/ml
nd control: 2.1± 0.3 FU/ml, respectively), TFPI (smokers:
5.8± 4.4 ng/ml and control: 18.4± 5.2 ng/ml, respec-
ively), and vWF (smokers: 62.8± 21.9% and control:
(PAI-1) and tissue plasminogen activator (t-PA) in smokers and
e are expressed as the mean± S.D. Controls, control subjects
y (p < 0.05) different from the control group.
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Figure 3 Plasma NO2− and NOX levels in smokers and control subjects. Plasma NO2− and NOX levels in the control state are
expressed as the mean± S.D. Controls, control subjects (n = 11); smokers, subjects who currently smoke (n = 9).
Figure 4 Relationship between plasma levels of plasminogen
activator inhibitor type 1 (PAI-1) and ﬂow-mediated vasodilation
(FMD). FMD in smokers (n = 11) and non-smokers (n = 9) were
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Figure 5 Relationship between plasma thrombomodulin (TM)
levels and ﬂow-mediated vasodilation (FMD). FMD in smokers
(n = 11) and non-smokers (n = 9) were plotted against TM levels.
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llotted against the PAI-1 levels. There was a signiﬁcant inverse
orrelation between these two parameters. Open circle, control
ubjects (non-smokers); closed circle, smokers.
6.3± 36.6%, respectively) levels in plasma were not
igniﬁcantly different between the two groups. PAI-1 lev-
ls correlated inversely with FMD (r =−0.451, p < 0.05)
Fig. 4) and TM levels correlated directly with FMD
r = 0.468, p < 0.05) (Fig. 5), respectively. Meanwhile,
O2− (r =−0.228), NOX (r =−0.213), t-PA (r =−0.153),
FPI (r = 0.265), and vWF (r = 0.170) did not correlate
ith the FMD. The amount and duration of smoking did
ot correlate signiﬁcantly with either the FMD or the
arious biomarkers. We did not ﬁnd any signiﬁcant cor-
elation among the biomarkers and lipid proﬁles in this
tudy.iscussion
n this study, endothelium-dependent (ﬂow-mediated) dila-
ion was impaired signiﬁcantly in the smokers compared
p
l
s
where was a signiﬁcant correlation between these two parame-
ers. Open circle, control subjects (non-smokers); closed circle,
mokers.
ith the control subjects, which was consistent with an
arly report suggesting an association between smoking
nd endothelial dysfunction [20,25]. The mechanism of
moking-induced endothelial dysfunction could be com-
lex and remains unclear. A large number of oxidants
nd oxygen-derived free radicals in the smoke likely
ontribute towards endothelial dysfunction [12—16]. More-
ver, smoke of cigarette is a source of nicotine and
hronic exposure results in nicotine-induced impairment
f endothelium-dependent arteriolar dilation [17]. From
hese points of view, it would be reasonable to postu-
ate that smoking-induced endothelial dysfunction most
ikely depends on increased oxidative stress and its toxic
roducts.NOX was measured as a possible marker of endothe-
ial function in all subjects, because plasma NOX levels in
mokers have been shown previously to be lower compared
ith non-smokers [26]. A tendency towards lower NOX lev-
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els in smokers compared with non-smokers was found in our
study. However, this difference was not statistically signiﬁ-
cant. Moreover, NOX levels did not correlate with FMD. Thus,
it would not be appropriate to use NOX levels to indicate
endothelial function, because NOX concentrations in plasma
are known to be inﬂuenced by various factors, including
food and drink [27] and because a recent study showed that
steady state NOX concentrations in whole blood and plasma
preferentially imply NOX elimination rather than NOX for-
mation [28]. Seventy to ninety percent of plasma NO2−, but
not NO3−, has been reported to originate from endothelial
nitric oxide synthase activity [29] and is now considered
to reﬂect nitric oxide synthase activity, based on several
investigations [30—32]. Therefore, we evaluated this sub-
stance separately. NO2− levels were not different between
the two groups and NO2− levels did not correlate with FMD.
NOX levels were about 100-fold of NO2− levels in this study.
Thus, more strict conditions would be necessary to evaluate
plasma NO2− levels in future.
Imbalances in the ﬁbrinolytic system may cause
microthrombi that will cause occlusion of the microcircu-
lation, and higher PAI-1 levels were observed in smokers
vs. healthy subjects [18] and in patients with angina pec-
toris [33], which is consistent with our ﬁndings. This higher
level of PAI-1 would be partly explained by the pharmaco-
logical effect of nicotine to increase PAI-1 mRNA expression
and protein production in endothelial cells [34]. Moreover,
oxidative stress in endothelial cells has been reported to
cause signiﬁcant increases in PAI-1 mRNA expression and
protein production [35]. Although we did not investigate
the mechanism of the increased PAI-1 in young smokers any
further, possible sources to increase PAI-1 would be solu-
ble substances in the serum, as Barua et al. have reported
that endothelial cells treated with serum isolated from
cigarette smokers exhibited enhanced PAI-1 production com-
pared with non-smokers [36]. Interestingly, recent studies
have revealed inhibitory effects of H2O2 and nicotine on the
expression and secretion of adiponectin in 3T3-L1 adipocytes
[37] and impaired endothelium-dependent vasorelaxation in
adiponectin-knockout mice [38]. In smokers, we observed
higher levels of both PAI-1 and t-PA. Increased plasma t-PA
levels have been reported in smokers with coronary risk fac-
tors [39], which would appear to be somewhat contradictory.
However, in the present study, the increase in t-PA was about
30% of the value in non-smokers, while the increase in PAI-
1 was about 130% (Fig. 2). In other words, the degree of
the increase in PAI-1 largely exceeded that of t-PA and the
imbalance could shift blood away from ﬁbrinolysis. Extra-
cellular generation of oxygen radicals by smoking may be
responsible for the increase in t-PA release and in t-PA
mRNA synthesis [40]. However, the higher level of plasma
t-PA does not necessarily imply a higher output (release) of
t-PA from endothelial cells. Indeed, such patients exhibit
impaired release of active t-PA after stimulation and an
inverse correlation exists between basal t-PA concentra-
tion and active t-PA release after endothelial stimulation
by substance P [39]. Therefore, the reduction in ﬁbrinolytic
capacity appears to reﬂect both impairment of acute t-PA
release and elevation of plasma PAI-1 concentrations. The
subsequent depletion of endothelial cell t-PA stores and con-
current increases in PAI-1 would impair the capacity of the
vasculature to lyse intraluminal thrombi, leading to future311
oronary events [41,42]. Further evaluation of any correla-
ion between functional changes (FMD) and its biochemical
arkers revealed that plasma PAI-1 levels correlated sig-
iﬁcantly with the endothelial function (FMD) among all
ubjects (smokers and non-smokers). Few prior studies have
elated plasma PAI-1 levels to measures of vascular func-
ion and an inverse correlation between plasma PAI-1 and
MD has been observed [43]. Therefore, increases in PAI-1
ould reﬂect the smoking-induced endothelial dysfunction
n the young male adults. Barua et al. demonstrated that
he basal t-PA/PAI-1 ratio was signiﬁcantly reduced in smok-
rs [36]. We assessed the t-PA/PAI-1 ratio between smokers
nd control subjects. T-PA/PAI-1 tended to be higher in con-
rol subjects; however, the relationship was not statistically
igniﬁcant.
Although TM levels in plasma were not signiﬁcantly differ-
nt between smokers and non-smokers, TM levels correlated
ith FMD among all subjects (smokers and non-smokers) in
his study. As correlations between TM and several biochem-
cal markers of endothelial dysfunction have been indicated
44], TM, as well as its oxidative modiﬁcation, would be
egarded as useful biomarkers for cigarette smoking [45].
There are several limitations to this study. First, the sam-
le size was relatively small. Therefore, the data would not
ear thorough analysis, i.e., stepwise multivariate analysis.
econd, we did not measure any markers of oxidative stress.
hird, we did not measure C-reactive protein (CRP), as a
orrelation between FMD in subcutaneous resistance arter-
es and CRP in male patients with coronary heart disease has
een reported previously [46]. Fourth, a possible contribu-
ion of higher HR on FMD in smokers remains unknown, as
ome studies indicated an interaction [47,48].
In conclusion, we demonstrated that FMD was attenuated
nd plasma levels of PAI-1 and t-PA were elevated in smok-
rs. These results suggest that chronic cigarette smoking
ould induce endothelial dysfunction. Thus, the PAI-1 level
ould be a good marker of endothelial dysfunction in these
oung smokers.
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